Analyst ratings are aggregated from multiple third-party sources and may be inaccurate, incomplete, or outdated. All ratings remain the sole responsibility of their original providers. Rankings are based on the 3-year performance of a simulated $100,000 account trading on analyst ratings data.
| Trades 711 | Longs Won 329/576 57% | Profit Factor 1.23 |
| Profitability | Shorts Won 57/135 42% | Standard Deviation $6,404.12 |
| Average Win $2,228.35 | Best Trade (Nov 30) $64,731.76 | Sharpe Ratio -59.93 |
| Average Loss -$2,155.74 | Worst Trade (Dec 28) -$66,154.13 | Z-Score -9.63 (100%) |
| Commissions $0 | Avg. Trade Length 2m | Expectancy $224.44 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | 0.16% | 1.09% | 3.41% | 7.64% | 14.29% | 23.84% | 36.74% | 53.45% | 74.4% |
| Consecutive Losing Trades | 120 | 108 | 96 | 84 | 72 | 60 | 48 | 36 | 24 | 12 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
FDMT 4D Molecular Therapeutics, Inc. | 21,018.48 | $304,557.77 | $259,578.23 | - | -$44,979.54 | -14.77% | -4.04% |